VALENTIS INC
PRES14A, 1999-06-11
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: TITAN TECHNOLOGIES INC, 10QSB, 1999-06-11
Next: AMERITAS LIFE INSURANCE CORP SEPARATE ACCOUNT LLVL, S-6/A, 1999-06-11



<PAGE>
                            SCHEDULE 14A INFORMATION

                  Proxy Statement Pursuant to Section 14(a) of
                      the Securities Exchange Act of 1934
                               (Amendment No.   )

    Filed by the Registrant                          / /
    Filed by a Party other than the Registrant         / /

    Check the appropriate box:
    /X/  Preliminary Proxy Statement
    / /  Confidential, for Use of the Commission Only (as permitted by Rule
         14a-6(e)(2))
    / /  Definitive Proxy Statement
    / /  Definitive Additional Materials
    / /  Soliciting Material Pursuant to Section240.14a-11(c) or
         Section240.14a-12

                                            VALENTIS, INC.
- --------------------------------------------------------------------------------
                (Name of Registrant as Specified In Its Charter)

- --------------------------------------------------------------------------------
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

/X/  No fee required.
/ /  Fee computed on table below per Exchange Act Rules 14a-6(i)(4)
     and 0-11.
     1.  Title of each class of securities to which transaction applies:
         -----------------------------------------------------------------------
     2.  Aggregate number of securities to which transaction applies:
         -----------------------------------------------------------------------
     3.  Per unit price or other underlying value of transaction computed
         pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
         filing fee is calculated and state how it was determined):
         -----------------------------------------------------------------------
     4.  Proposed maximum aggregate value of transaction:
         -----------------------------------------------------------------------
     5.  Total fee paid:
         -----------------------------------------------------------------------
/ /  Fee paid previously with preliminary materials.
/ /  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.
     6.  Amount Previously Paid:
         -----------------------------------------------------------------------
     7.  Form, Schedule or Registration Statement No.:
         -----------------------------------------------------------------------
     8.  Filing Party:
         -----------------------------------------------------------------------
     9.  Date Filed:
         -----------------------------------------------------------------------
<PAGE>
                                 VALENTIS, INC.
                                863A MITTEN ROAD
                          BURLINGAME, CALIFORNIA 94010

                            ------------------------

                   NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
                          TO BE HELD ON JULY 30, 1999

                            ------------------------

To the Stockholders of

  VALENTIS, INC.:

    NOTICE IS HEREBY GIVEN that a Special Meeting of Stockholders of VALENTIS,
INC., a Delaware corporation (the "Company"), will be held on Friday, July 30,
1999, at 10:00 a.m. local time at the offices of the Company, 863A Mitten Road,
Burlingame, California 94010 for the following purpose:

    1.  To approve an amendment to the Company's Amended and Restated
       Certificate of Incorporation to increase the authorized number of shares
       of the Company's Common Stock from 30,000,000 to 45,000,000.

    2.  To transact such other business as may properly come before the meeting
       or any adjournment or postponement thereof.

    The foregoing items of business are more fully described in the Proxy
Statement accompanying this Notice.

    The Board of Directors has fixed the close of business on June 24, 1999, as
the record date for the determination of stockholders entitled to notice of and
to vote at this Special Meeting and at any adjournment or postponement thereof.

                                          By Order of the Board of Directors

                                          /s/ Patrick A. Pohlen
                                          Patrick A. Pohlen
                                          SECRETARY

Burlingame, California
June [  ], 1999

ALL STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE MEETING IN PERSON. WHETHER
OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE, SIGN AND RETURN
THE ENCLOSED PROXY AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR
REPRESENTATION AT THE MEETING. A RETURN ENVELOPE (WHICH IS POSTAGE PREPAID IF
MAILED IN THE UNITED STATES) IS ENCLOSED FOR THAT PURPOSE. EVEN IF YOU HAVE
GIVEN YOUR PROXY, YOU MAY STILL VOTE IN PERSON IF YOU ATTEND THE MEETING. PLEASE
NOTE, HOWEVER, THAT IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER
NOMINEE AND YOU WISH TO VOTE AT THE MEETING, YOU MUST OBTAIN FROM THE RECORD
HOLDER A PROXY ISSUED IN YOUR NAME.
<PAGE>
                                 VALENTIS, INC.
                                863A MITTEN ROAD
                          BURLINGAME, CALIFORNIA 94010

                            ------------------------

                                PROXY STATEMENT
                      FOR SPECIAL MEETING OF STOCKHOLDERS
                                 TO BE HELD ON
                                 JULY 30, 1999

                            ------------------------

                 INFORMATION CONCERNING SOLICITATION AND VOTING

GENERAL

    The enclosed proxy is solicited on behalf of the Board of Directors of
Valentis, Inc., a Delaware corporation (the "Company"), for use at the Special
Meeting of Stockholders to be held on July 30, 1999, at 10:00 a.m. local time
(the "Special Meeting"), or at any adjournment or postponement thereof, for the
purposes set forth herein and in the accompanying Notice of Special Meeting. The
Special Meeting will be held at the offices of the Company, 863A Mitten Road,
Burlingame, California 94010. The Company intends to mail this proxy statement
and accompanying proxy card on or about June 28, 1999, to all stockholders
entitled to vote at the Special Meeting.

SOLICITATION

    The Company will bear the entire cost of solicitation of proxies, including
preparation, assembly, printing and mailing of this proxy statement, the proxy
and any additional information furnished to stockholders. Copies of solicitation
materials will be furnished to banks, brokerage houses, fiduciaries and
custodians holding in their names shares of Common Stock beneficially owned by
others to forward to such beneficial owners. The Company may reimburse persons
representing beneficial owners of Common Stock for their costs of forwarding
solicitation materials to such beneficial owners. Original solicitation of
proxies by mail may be supplemented by telephone, telegram or personal
solicitation by directors, officers or other regular employees of the Company.
No additional compensation will be paid to directors, officers or other regular
employees for such services.

VOTING RIGHTS AND OUTSTANDING SHARES

    Only holders of record of Common Stock at the close of business on June 24,
1999 will be entitled to notice of and to vote at the Special Meeting. At the
close of business on [June 24, 1999], the Company had outstanding and entitled
to vote [NUMBER] shares of Common Stock.

    Each holder of record of Common Stock on such date will be entitled to one
vote for each share held on all matters to be voted upon at the Special Meeting.

    All votes will be tabulated by the inspector of election appointed for the
meeting, who will separately tabulate affirmative and negative votes,
abstentions and broker non-votes. Abstentions will be counted towards the
tabulation of votes cast on proposals presented to the stockholders and will
have the same effect as negative votes. Broker non-votes are counted towards a
quorum, but are not counted for any purpose in determining whether a matter has
been approved. With respect to Proposal 1, abstentions and broker non-votes will
have the same effect as negative votes.
<PAGE>
REVOCABILITY OF PROXIES

    Any person giving a proxy pursuant to this solicitation has the power to
revoke it at any time before it is voted. It may be revoked by filing with the
Secretary of the Company at the Company's principal executive office, 863A
Mitten Road, Burlingame, California 94010, a written notice of revocation or a
duly executed proxy bearing a later date, or it may be revoked by attending the
meeting and voting in person. Attendance at the meeting will not, by itself,
revoke a proxy.

STOCKHOLDER PROPOSALS

    Proposals of stockholders that are intended to be presented at the Company's
1999 Annual Meeting of Stockholders must be received by the Company not later
than June 30, 1999, in order to be included in the proxy statement and proxy
relating to that Annual Meeting. Stockholders are also advised to review the
Company's Bylaws, which contain additional requirements with respect to advance
notice of stockholder proposals and director nominations.

                                       2
<PAGE>
                                   PROPOSAL 1
                       APPROVAL OF INCREASE IN NUMBER OF
                       AUTHORIZED SHARES OF COMMON STOCK

    The Board of Directors has adopted, subject to stockholder approval, an
amendment to the Company's Amended and Restated Certificate of Incorporation to
increase the Company's authorized number of shares of Common Stock from
30,000,000 shares to 45,000,000 shares.

    The additional Common Stock to be authorized by adoption of the amendment
would have rights identical to the currently outstanding Common Stock of the
Company. Adoption of the proposed amendment and issuance of the Common Stock
would not affect the rights of the holders of currently outstanding Common Stock
of the Company, except for effects incidental to increasing the number of shares
of the Company's Common Stock outstanding, such as dilution of the earnings per
share and voting rights of current holders of Common Stock. If the amendment is
adopted, it will become effective upon filing of a Certificate of Amendment of
the Company's Amended and Restated Certificate of Incorporation with the
Secretary of State of the State of Delaware.

    In addition to the 22,070,803 shares of Common Stock outstanding at April
30, 1999, the Board of Directors has reserved 3,920,483 shares for issuance upon
exercise of options and rights granted under the Company's stock option and
stock purchase plans, and 76,133 shares of Common Stock which may be issued upon
exercise of warrants currently outstanding.

    The Board of Directors desires to have such shares available to provide
additional flexibility to use its capital stock for business and financial
purposes in the future. The additional shares may be used, without further
stockholder approval, for various purposes including, without limitation,
raising capital, providing equity incentives to employees, officers or
directors, establishing strategic relationships with other companies and
expanding the company's business or product lines through the acquisition of
other businesses or products.

    The additional shares of Common Stock that would become available for
issuance if the proposal were adopted could also be used by the Company to
oppose a hostile takeover attempt or delay or prevent changes in control or
management of the Company. For example, without further stockholder approval,
the Board of Directors could adopt a "poison pill" which would, under certain
circumstances related to an acquisition of shares not approved by the Board of
Directors, give certain holders the right to acquire additional shares of Common
Stock at a low price, or the Board of Directors could strategically sell shares
of Common Stock in a private transaction to purchasers who would oppose a
takeover or favor the current Board of Directors. Although this proposal to
increase the authorized Common Stock has been prompted by business and financial
considerations and not by the threat of any hostile takeover attempt (nor is the
Board of Directors currently aware of any such attempts directed at the
Company), nevertheless, stockholders should be aware that approval of proposal
could facilitate future efforts by the Company to deter or prevent changes in
control of the Company, including transactions in which the stockholders might
otherwise receive a premium for their shares over then current market prices.

    The affirmative vote of the holders of a majority of the shares of the
Company's Common Stock, will be required to approve this amendment to the
Company's Amended and Restated Certificate of Incorporation. As a result,
abstentions and broker non-votes will have the same effect as negative votes.

                       THE BOARD OF DIRECTORS RECOMMENDS
                         A VOTE IN FAVOR OF PROPOSAL 1.

                                       3
<PAGE>
                             SECURITY OWNERSHIP OF
                    CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

    The following table sets forth certain information regarding the ownership
of the Company's Common Stock as of April 30, 1999 by: (i) each director; (ii)
all individuals who have served as the Company's Chief Executive Officer during
the fiscal year ended June 30, 1998; (iii) the Company's other most highly
compensated executive officers as of June 30, 1998; (iv) all executive officers
and directors of the Company as a group; and (v) all those known by the Company
to be beneficial owners of more than five percent of its Common Stock.

<TABLE>
<CAPTION>
                                                                        BENEFICIAL OWNERSHIP (1)
                                                                        ------------------------
                                                                        NUMBER OF    PERCENT OF
BENEFICIAL OWNER                                                          SHARES        TOTAL
- ----------------------------------------------------------------------  ----------   -----------
<S>                                                                     <C>          <C>
Entities affiliated with Roche Holding Ltd(2).........................   1,713,665        7.76%
  Grenzacherstrasse 124, CH-4070
  Basel, Switzerland

Benjamin F. McGraw, III, Pharm.D.(3)..................................     406,703        1.84

Frank J. Caufield(4)..................................................     340,289        1.54

Patrick G. Enright(5).................................................     199,499           *

Russell C. Hirsch, M.D., Ph.D.(6).....................................       6,633           *

Raju Kucherlapati(7)..................................................      25,832           *

Rodney Pearlman(8)....................................................     131,811           *

Arthur M. Pappas......................................................       3,997           *

Bert W. O'Malley, M.D.(9).............................................      73,543           *

Stanley T. Crooke, M.D., Ph.D.(10)....................................      23,808           *

All executive officers and directors as a group (11 persons)(11)......   1,233,781        5.65
</TABLE>

- ------------------------

   * Less than one percent.

 (1) This table is based upon information supplied by officers, directors and
     principal stockholders and Schedules 13D and 13G if any filed with the
     Securities and Exchange Commission (the SEC). Unless otherwise indicated in
     the footnotes to this table and subject to community property laws where
     applicable, the Company believes that each of the stockholders named in
     this table has sole voting and investment power with respect to the shares
     indicated as beneficially owned. Applicable percentages are based on
     22,070,803 shares outstanding on April 30, 1999, adjusted as required by
     rules promulgated by the SEC.

 (2) Includes 611,785 shares and 1,101,880 shares of Common Stock beneficially
     held by Syntex Corporation ("Syntex") and Corange International Limited
     ("Corange"), respectively. Syntex and Corange are affiliates of Roche
     Holding Ltd, a Swiss corporation.

 (3) Includes 373,333 shares Dr. McGraw acquired pursuant to the exercise of
     stock options, 37,848 of which will be subject to repurchase by the Company
     as of June 29, 1999.

 (4) Includes 5,000 shares Mr. Caufield has the right to acquire pursuant to
     outstanding options exercisable within 60 days.

 (5) Includes 2,000 shares held by Enright Capital Advisors, an investment
     partnership of which Mr. Enright is a partner. Mr. Enright disclaims
     beneficial ownership of all such shares owned by the foregoing partnership
     except to the extent of his proportionate pecuniary interest therein. Also

                                       4
<PAGE>
     includes 85,000 shares Mr. Enright has the right to acquire pursuant to
     outstanding options exercisable within 60 days.

 (6) Includes 5,000 shares Dr. Hirsch has the right to acquire pursuant to
     outstanding options exercisable within 60 days.

 (7) Includes 25,832 shares Dr. Kucherlapati has the right to acquire pursuant
     to outstanding options exercisable within 60 days.

 (8) Includes 112,499 shares Dr. Pearlman acquired pursuant to the exercise of
     stock options, 4,254 of which will be subject to repurchase by the Company
     as of June 29, 1999. Also includes 14,062 shares Dr. Pearlman has the right
     to acquire pursuant to outstanding options exercisable within 60 days.

 (9) Includes 39,629 shares Dr. O'Malley has the right to acquire pursuant to
     outstanding options exercisable within 60 days.

 (10) Includes 13,204 shares Dr. Crooke has the right to acquire pursuant to
      outstanding options exercisable within 60 days.

 (11) Includes 209,393 shares subject to options exercisable within 60 days.

CERTAIN TRANSACTIONS

    The Company has entered into indemnity agreements with certain officers and
directors which provide, among other things, that the Company will indemnify
such officer or director, under the circumstances and to the extent provided for
therein, for expenses, damages. Judgments, fines and settlements he may be
required to pay in actions or proceedings which he is or may be made a party by
reason of his position as a director, officer or other agent of the Company, and
otherwise to the full extent permitted under Delaware law and the Company's
Bylaws.

                                 OTHER MATTERS

    The Board of Directors knows of no other matters that will be presented for
consideration at the Annual Meeting. If any other matters are properly brought
before the meeting, it is the intention of the persons named in the accompanying
proxy to vote on such matters in accordance with their best judgment.

                                          By Order of the Board of Directors

                                          /s/ Patrick A. Pohlen
                                          Patrick A. Pohlen
                                          SECRETARY

           , 1999

                                       5
<PAGE>

                                   DETACH HERE

                                 VALENTIS, INC.
                    PROXY SOLICITED BY THE BOARD OF DIRECTORS
                     FOR THE SPECIAL MEETING OF STOCKHOLDERS
                           TO BE HELD ON JULY 30, 1999

     The undersigned hereby appoints BENNET L. WEINTRAUB and PATRICK A. POHLEN,
and each of them, as attorneys and proxies of the undersigned, with full power
of substitution, to vote all of the shares of common stock of Valentis, Inc.
(the "Company") which the undersigned may be entitled to vote at the Special
Meeting of Stockholders to be held at the Company's offices at 863A Mitten Road,
Burlingame, California 94010, on Friday, July 30, 1999 at 10:00 a.m. (local
time), and at any and all postponements, continuations and adjournments thereof,
with all powers that the undersigned would possess if personally present, upon
and in respect of the following matters and in accordance with the following
instructions, with discretionary authority as to any and all other matters that
may properly come before the meeting.

     UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR
PROPOSAL 1, AS MORE SPECIFICALLY DESCRIBED IN THE PROXY STATEMENT. IF SPECIFIC
INSTRUCTIONS ARE INDICATED, THIS PROXY WILL BE VOTED IN ACCORDANCE THEREWITH.

MANAGEMENT RECOMMENDS A VOTE FOR PROPOSAL 1.

PROPOSAL 1:    To approve an amendment to the Company's Amended and Restated
               Certificate of Incorporation to increase the authorized number of
               shares of common stock from 30,000,000 to 45,000,000 shares.

       / / FOR                      / / AGAINST               / / ABSTAIN

                   (CONTINUED AND TO BE SIGNED ON OTHER SIDE)

<PAGE>

                           (CONTINUED FROM OTHER SIDE)

DATED:
       -----------------------------   -----------------------------------------


                                       -----------------------------------------
                                                       SIGNATURE(S)

                                       PLEASE SIGN EXACTLY AS YOUR NAME APPEARS
                                       HEREON. IF THE STOCK IS REGISTERED IN
                                       THE NAMES OF TWO OR MORE PERSONS, EACH
                                       SHOULD SIGN. EXECUTORS, ADMINISTRATORS,
                                       TRUSTEES, GUARDIANS AND
                                       ATTORNEYS-IN-FACT SHOULD ADD THEIR
                                       TITLES. IF SIGNER IS A CORPORATION,
                                       PLEASE GIVE FULL CORPORATE NAME AND HAVE
                                       A DULY AUTHORIZED OFFICER SIGN, STATING
                                       TITLE. IF SIGNER IS A PARTNERSHIP,
                                       PLEASE SIGN IN PARTNERSHIP NAME BY
                                       AUTHORIZED PERSON.

PLEASE VOTE, DATE AND PROMPTLY RETURN THIS PROXY IN THE ENCLOSED RETURN ENVELOPE
WHICH IS POSTAGE PREPAID IF MAILED IN THE UNITED STATES.


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission